Ra Pharmaceuticals Inc (NASDAQ:RARX) – Analysts at Jefferies Group issued their Q3 2016 EPS estimates for shares of Ra Pharmaceuticals in a research note issued to investors on Monday. Jefferies Group analyst E. Yang expects that the firm will post earnings of ($0.47) per share for the quarter. Jefferies Group has a “Buy” rating and a $25.00 price objective on the stock. Jefferies Group also issued estimates for Ra Pharmaceuticals’ Q4 2016 earnings at ($0.37) EPS, FY2016 earnings at ($1.72) EPS, Q1 2017 earnings at ($0.39) EPS, Q2 2017 earnings at ($0.49) EPS, Q3 2017 earnings at ($0.68) EPS, Q4 2017 earnings at ($0.91) EPS, FY2017 earnings at ($1.97) EPS, FY2018 earnings at ($3.13) EPS, FY2019 earnings at ($0.01) EPS and FY2020 earnings at ($3.82) EPS.

Earnings History and Estimates for Ra Pharmaceuticals (NASDAQ:RARX)

A number of other equities analysts also recently commented on RARX. BMO Capital Markets began coverage on Ra Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $26.00 price target for the company. Credit Suisse Group AG began coverage on Ra Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $19.00 price target for the company. Finally, SunTrust Banks Inc. began coverage on Ra Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $32.00 price target for the company.

Shares of Ra Pharmaceuticals (NASDAQ:RARX) traded up 0.577% during trading on Wednesday, hitting $13.075. The stock had a trading volume of 37,715 shares. The firm’s market cap is $7.24 million. The firm’s 50-day moving average is $13.18 and its 200-day moving average is $13.18. Ra Pharmaceuticals has a one year low of $12.33 and a one year high of $14.86.

In related news, major shareholder Harry R. Weller bought 338,462 shares of the firm’s stock in a transaction on Monday, October 31st. The stock was bought at an average cost of $13.00 per share, for a total transaction of $4,400,006.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rajeev M. Shah bought 161,538 shares of the firm’s stock in a transaction on Monday, October 31st. The stock was bought at an average price of $13.00 per share, with a total value of $2,099,994.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY NOTICE: “Ra Pharmaceuticals Inc to Post Q3 2016 Earnings of ($0.47) Per Share, Jefferies Group Forecasts (RARX)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/23/ra-pharmaceuticals-inc-to-post-q3-2016-earnings-of-0-47-per-share-jefferies-group-forecasts-rarx.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

5 Day Chart for NASDAQ:RARX

Receive News & Stock Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.